Stay updated with breaking news from விழித்திரை கண். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AI-supported test can predict eye disease that leads to blindness | Imperial News imperial.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imperial.ac.uk Daily Mail and Mail on Sunday newspapers.
AI-supported test can predict eye disease that leads to blindness miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
AI-supported test can predict eye disease that leads to blindness | Imperial News imperial.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imperial.ac.uk Daily Mail and Mail on Sunday newspapers.
More than thirty years after discovering Leber’s hereditary optic neuropathy (LHON) as the first maternally inherited disease associated with homoplasmic mtDNA mutations, we still struggle to achieve effective therapies. LHON is characterized by selective degeneration of retinal ganglion cells (RGCs) and is the most frequent mitochondrial disease, which leads to blindness young people, in particular males. Despite the causative mutations are present in all tissues, yet only a specific cell type is affected. Our deep understanding of the pathogenic mechanisms in LHON is hampered by the lack of appropriate models since investigations have been traditionally performed in non-neuronal cells. Effective in vitro models of LHON are now emerging, casting promise to speed our understanding of pathophysiology and test therapeutic strategies to accelerate translation into clinic. We here review the potentials of these new models and their impact on the future of LHON patients. ....
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD 04/07/2021 | 11:45am EDT Send by mail : Message : Required fields Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, announces the publication of a review article describing the cutting-edge science and rationale for the design and development of THR-687. The article entitled: ....